What does Bicara Therapeutics Inc. do?
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human…
What is Bicara Therapeutics Inc.'s P/E and P/B ratio?
Bicara Therapeutics Inc. has a P/E ratio of -5.5 and a P/B ratio of 2.41.
What is Bicara Therapeutics Inc.'s debt-to-equity ratio?
Bicara Therapeutics Inc. has a debt-to-equity ratio of 0.00.
How much does Bicara Therapeutics Inc. owe compared with what it owns?
Bicara Therapeutics Inc. owes $0.08 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Bicara Therapeutics Inc.'s Positivity rank?
Bicara Therapeutics Inc. is ranked #3,619 of 6,775 companies globally and #1,581 of 3,999 in United States on PositoAI, with a Positivity Score of 20,436.
Does Bicara Therapeutics Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Bicara Therapeutics Inc..
Where can I read the latest news about Bicara Therapeutics Inc.?
Recent headlines about Bicara Therapeutics Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Bicara Therapeutics Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Bicara Therapeutics Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.